Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003002 in Single and Multiple Ascending Dose Randomized Doubled-blind Phase 1 Study in Healthy Subjects
Latest Information Update: 21 Jun 2023
At a glance
- Drugs JMKX 003002 (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Jemincare
Most Recent Events
- 21 Jun 2023 New trial record